1-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazine → HCID 54675480, 화합물

HRID 2411615노트

반응식

HRID 2411615 반응식
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH:19]1([C:22]2[CH:23]=[C:24]([CH3:34])[C:25]([N:28]3[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]3)=[N:26][CH:27]=2)[CH2:21][CH2:20]1>>[CH:19]1([C:22]2[CH:23]=[C:24]([CH3:34])[C:25]([N:28]3[CH2:29][CH2:30][N:31]([C:11]([C:10]4[C:9]([CH3:17])=[N:8][C:7]([N:3]5[CH2:4][CH2:5][CH2:6][S:2]5(=[O:1])=[O:18])=[CH:16][CH:15]=4)=[O:13])[CH2:32][CH2:33]3)=[N:26][CH:27]=2)[CH2:21][CH2:20]1

참가 물질

3

반응물 2

HCID 584847181-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, 화합물

생성물 1

HCID 54675480HCID 54675480, 화합물수율 58.3%

실험 절차

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (300 mg) described in Preparation Example 37 and 1-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine (265 mg) described in Preparation Example 83 and by the reaction and treatment in the same manner as in Example 109, the title compound (295 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 83 and by the reaction and treatment in the same manner as in Example 109

출처 및 근거

ORD 기록
ord-1eaa2a7ea87f4f1e87bd10809d14d37f
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08816079B2

반응 노트

불러오는 중…